A Phase 2b Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 6-Valent Group B <i>Streptococcus</i> Vaccine Administered Concomitantly With Tetanus, Diphtheria, and Acellular Pertussis Vaccine in Healthy Nonpregnant Female Individuals
GBS6 and Tdap administered concomitantly and alone were safe and well tolerated in healthy nonpregnant individuals. Similar immune responses were observed for Tdap when administered with GBS6 or when administered alone. These results will likely inform future studies in pregnant individuals. Clinical Trials Registration. NCT04766086.
Authors
- Annaliesa S. Anderson (ORCID: https://orcid.org/0000-0002-6413-1718)
- William Seger
- Babalwa Jongihlati (ORCID: https://orcid.org/0000-0002-9137-2541)
- Natalie C. Silmon de Monerri (ORCID: https://orcid.org/0000-0001-5480-6606)
- Johannes Beeslaar (ORCID: https://orcid.org/0000-0003-0454-3515)
- Richard Chawana
- William B. Smith (ORCID: https://orcid.org/0000-0002-6907-9031)
- Kara Bickham (ORCID: https://orcid.org/0000-0003-0651-9236)
- Julie M. Skinner (ORCID: https://orcid.org/0000-0003-4522-0472)
- Zahra Jefferies
- Feng Ye (ORCID: https://orcid.org/0000-0002-5953-6024)
- Michelle Gaylord
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- JPS Health Network (US)
- Alliance for Multispecialty Research (United States) (US)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1093/infdis/jiaf096
- Citations
- 9
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 10.65